ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts.
Merck has submitted a Biologics License Application (BLA) to the FDA for its house dust mite (HDM) sublingual allergy immunotherapy...
Objectives: To assess the association of whole grain consumption with the risk of incident knee OA.
Merck announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite...
Circassia Pharmaceuticals plc announces top-line results from its investigational house dust mite allergy immunotherapy phase IIb field study. In the...
Astellas Pharma Inc. and iota Biosciences, Inc. announced that Astellas through a U.S. subsidiary, and iota have entered into a Merger Agreement pursuant to which Astellas will acquire iota.
ALK has announced that its house dust mite sublingual allergy immunotherapy (SLIT) tablet Acarizax has had its approval in 12...
ALK has obtained European approval for its HDM-SLIT (house dust mite sublingual allergy immunotherapy tablet) against allergic rhinitis and allergic...
ALK Abello announced positive top-line results from the pivotal Phase III MITRA trial conducted with the allergy immunotherapy tablet against...
Results also show that gout is more than twice as likely in alcoholic patients and more than three times as likely in obese patients.1